Urology
Volume 75, Issue 2 , Pages 405-406 , February 2010

Reply

References 

  1. Schroeder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality in a randomized European trial. N Engl J Med. 2009;360:1320–1328
  2. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149:185–191
  3. Brawley OW, Ankerst DP, Thompson IM. Screening for prostate cancer. CA Cancer J Clin. 2009;59:264–273
  4. van der Cruijsen-Koeter IW, Roobol MJ, Wildhagen MF, et al. Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam. Urology. 2006;68:615–620
  5. Roobol MJ, Grenabo A, Schroeder FH, et al. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2007;99:1296–1303
  6. Lu-Yao GL, Albertsen PC, Moore DF. Outcomes of localized prostate cancer following conservative management. JAMA. 2009;302:1202–1209
  7. Bill-Axelson A, Holmberg L, Filen F, et al. Scandinavian Prostate Cancer Group study number 4 (Radical prostatectomy versus watchful waiting in localized prostate cancer). J Natl Cancer Inst. 2008;100:1144–1154
  8. Miller DC, Gruber SB, Hollenback BK, et al. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst. 2006;98:1134–1141
  9. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–224

PII: S0090-4295(09)02620-X

doi: 10.1016/j.urology.2009.09.031

Urology
Volume 75, Issue 2 , Pages 405-406 , February 2010

Article Tools